SAHA
Term · Oncology and biomedicine · MLC-T-ONC-007535
A drug used to treat cutaneous T-cell lymphoma that came back, got worse, or did not get better during or after treatment with two systemic therapies. It is also being studied in the treatment of other types of cancer. SAHA blocks certain enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase inhibitor. Also called suberoylanilide hydroxamic acid, vorinostat, and Zolinza.
| Identifier | MLC-T-ONC-007535 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | suberoylanilide hydroxamic acid; vorinostat; Zolinza |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-007535",
"term": "SAHA",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat cutaneous T-cell lymphoma that came back, got worse, or did not get better during or after treatment with two systemic therapies. It is also being studied in the treatment of other types of cancer. SAHA blocks certain enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase inhibitor. Also called suberoylanilide hydroxamic acid, vorinostat, and Zolinza.",
"expansions": [
"suberoylanilide hydroxamic acid",
"vorinostat",
"Zolinza"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/saha/"
}
Record 14,644 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.